MSB

1.02%

99.0¢ mesoblast limited

MSB Monday Opening Price, page-140

First 140 Last

Share
Profile

Follow
redbaron

2,030 Posts.

82

26/04/20

23:30

Post #: 44267943
Share

Originally posted by mja: ↑

I have analysed various studies for remestemcel, over the last few days. Of note there appear to be minimal side effects, no difference versus placebo. This cannot be understated, as "first do know harm" is a key medical axiom.

I have just reviewed another study.

Title: Factors associated with hospitalization and critical illness among 4,103 patients with
Covid-19 disease in New York City

The study ran from March 1 2020 to April 2 2020, with results compiled as at April 7 2020.

445 patients in this study received mechanical ventilation (intubated). The results were:
-16 discharged 3.6%
-162 died 36.4%
-22 extubated (off ventilation), still in hospital 4.9%
-245 still ventilated 55.1%

So 8.5% have had a good outcome, ie discharged or extubated. 36.4% have died. 55.1% are still intubated (receiving mechanical ventilation), and the longer you are ventilated the less likely you are to have a good outcome. These numbers in my opinion would be consistent with at least a 75% mortality rate. This study appears to give the best indication as to the present condition of the patients not discharged or deceased in the studies cited earlier, ie 91.8% of the inpatients (not discharged or deceased) are still being ventilated in the above study.

Remestemcel in comparison had:
-7 discharged 58.3%
-2 died 16.7%
-2 extubated, still in hospital 16.7%
-1 still ventilated 8.3%
--so 75% have had a good outcome with remestemcel, versus 8.5% in above study. The sample size is small, but the results are compelling. The other key is that the remestemcel targets the pathway that triggers ARDS, and has achieved statistically significant results in graft versus host disease post bone marrow transplant, with nil side effects of note. Graft versus host disease and ARDS can both be looked on as being autoimmune in nature ie the body inadvertently attacking itself. As opposed to we gave this medication and it seemed to help, but we are not entirely sure of the mechanism to action.

Expand

Let me know if you come across the Clinical Trial that Mesoblast is doing now for FDA approval, description and design etc...
GLA

MSB Price at posting: $2.73 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

RCE

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 173 more messages in this thread...

First 140 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 99.0¢		Change 0.010(1.02%)		Mkt cap ! $1.130B

Open	High	Low	Value	Volume
99.5¢	$1.02	98.5¢	$5.507M	5.501M

Buyers (Bids)

No.	Vol.	Price($)
1	9996	99.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.5¢	18069	3

View Market Depth

No.	Vol.	Price($)
1	9996	0.990
2	32880	0.985
4	71034	0.980
2	3059	0.975
7	145890	0.970

Price($)	Vol.	No.
0.995	1132	1
1.000	9500	3
1.005	35000	1
1.010	58113	4
1.015	46100	3

Last trade - 16.10pm 28/06/2024 (20 minute delay)

MSB (ASX) Chart

MSB Monday Opening Price, page-140

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB Monday Opening Price, page-140

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News